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Purpose: People with COPD have cognitive dysfunction, which is greater in those hospitalized 
for exacerbations than in stable outpatients. We tested the hypothesis that cognitive dysfunc-
tion at exacerbation is a disease-specific feature of COPD, rather than a nonspecific feature of 
hospitalization for acute illness, by comparing cognition between patients hospitalized for acute 
COPD exacerbations and those with worsening heart failure (HF).
Patients and methods: A total of 40 hospital inpatients were recruited, 20 patients with 
COPD exacerbations and 20 patients with congestive or left-sided HF. Exclusion criteria 
included previous stroke, known neurological disease, and marked alcohol excess. Participants 
completed the Montreal cognitive assessment (MoCA) and Hospital Anxiety and Depression 
Scale (HADS) and underwent spirometry and review of clinical records.
Results: Age (mean±SD, COPD 73±10; HF 76±11 years), acute illness severity (Acute 
Physiology and Chronic Health Evaluation [APACHE]-II, COPD 15.4±3.5; HF 15.9±3.0), 
comorbidities (Charlson index, COPD 1.3±1.9; HF 1.6±1.5), and educational background were 
similar between COPD and HF groups. MoCA total was significantly lower in COPD than in HF 
(COPD 20.6±5.6; HF 24.8±3.5, P=0.007); however, significance was lost after correction for 
age, sex, and pack year smoking history. When compared with HF patients, the COPD cohort 
performed worse on the following domains of the MoCA: visuospatial function (median [IQR], 
COPD 0 [1]; HF 2 [1], P=0.003), executive function (COPD 2 [1]; HF 3 [1], P=0.035), and 
attention (COPD 4 [3]; HF 6 [2], P=0.020). Age (P=0.012) and random glucose concentration 
(P=0.041) were associated with cognitive function in whole group analysis, with pack year 
smoking history reaching borderline significance (P=0.050).
Conclusion: Total MoCA score for COPD and HF indicated that both groups had mild cogni-
tive impairment, although this was greater in people with COPD. Mechanisms underlying the 
observed cognitive dysfunction in COPD remain unclear but appear related to blood glucose 
concentrations and greater lifetime smoking load.
Keywords: Montreal cognitive assessment, cognition, comorbidities, systemic, smoking, 
hyperglycemia
Introduction
Cognitive dysfunction is common in people with COPD. In a recent systematic 
review, cognitive impairment was reported to affect one in three COPD patients.1 
Impaired cognition in people with COPD is associated with reduced treatment 
adherence, impaired performance in daily activities, and increased mortality. For 
example, in an observational study of 157 patients referred for pulmonary rehabili-
tation, patients with cognitive impairment were twice as likely to fail to complete 
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the program as those without.2 In a systematic review of 
13 studies assessing the impact of cognitive impairment 
on self-management in COPD, cognitive dysfunction was 
associated with an increased need for assistance in activities 
of daily living, reduced symptom recall, and increased errors 
in inhaler technique.3 Understanding what drives cognitive 
impairment in people with COPD is therefore important in 
order to identify factors that could be modified to improve 
health outcomes.
Mild cognitive impairment refers to a decline in cog-
nition, which presents as the intermediary stage between 
normal cognitive aging and dementia, independent of edu-
cational level and not severe enough to interfere with daily 
activities.4 Longitudinal studies have reported that one-half of 
individuals who meet the criteria for mild cognitive impair-
ment develop dementia within 3 years.5
While the mechanisms that underlie cognitive impair-
ment in COPD are not completely understood and are 
likely to be multifactorial, COPD-specific factors have been 
proposed.6 These include hypoxemia,7 disease severity,8 
reduced physical activity,9 and exacerbations.10,11 Hospi-
talization due to the exacerbations of COPD in particular 
appears to be a high risk for cognitive dysfunction. A study 
comparing 30 COPD patients hospitalized with exacer-
bations, 50 stable COPD patients, and 30 age-matched 
healthy controls found that 50% of hospitalized patients 
had impaired processing speed compared to 24% of stable 
COPD patients and 3% of controls.11 Moreover, hospitalized 
patients deemed medically fit for discharge had significant 
deficits in cognitive function, which had not improved 
3 months after discharge.11 In a 2-year prospective cohort 
study of patients hospitalized with COPD exacerbations, 
baseline assessment of cognitive function was significantly 
worse in those who died during follow-up than in those who 
survived.12 What remains unclear is whether the cognitive 
dysfunction seen in hospitalized COPD patients is due to a 
COPD-specific effect or rather a nonspecific effect of acute 
illness and hospitalization itself.
The hypothesis underlying this study is that patients 
hospitalized due to COPD exacerbations are more likely to 
have cognitive impairment than those hospitalized with dec-
ompensation of other chronic illnesses, due to COPD-specific 
factors. To test this hypothesis, we compared the prevalence 
of cognitive impairment in hospitalized patients with COPD 
exacerbations and decompensated heart failure (HF) and 
investigated the relationship between cognitive impairment 
and clinical characteristics within disease groups.
Methods
Design
This was a prospective case–control study. All participants 
gave written informed consent. The study was approved 
by the West Midlands Research Ethics Committee (13/
WM/0434).
Patient selection
Patients admitted to hospital with the exacerbations of COPD 
were recruited and compared with patients hospitalized with 
decompensated HF. HF patients were selected as a control 
group for comparison with COPD patients because a similarly 
high prevalence of cognitive impairment has been reported 
in both diseases.1 They were also expected to be comparable 
in terms of age and comorbidities.
Inclusion criteria
COPD patients were identified on admission with a physician 
diagnosis of an acute exacerbation of COPD. Participants had 
symptoms of exacerbation (cough, sputum, and breathless-
ness), a significant smoking history (.10 pack years), and 
obstructive spirometry (ratio of FEV
1
 to FVC ,0.7).
HF patients were identified on admission with a physi-
cian diagnosis of decompensated HF. Participants had 
edema and/or dyspnea, a prior diagnosis of HF, evidence of 
reduced ejection fraction, and/or diastolic dysfunction on 
echocardiogram.
exclusion criteria
Patients were excluded if they had combined COPD and 
HF, asthma, pneumonia, past medical history of stroke, 
neurological disorder, psychiatric disorder, marked alcohol 
excess (male .56 U/week, female .42 U/week), or severe 
renal failure (.500 μmol/L creatinine) (Figure 1).
Clinical measures
Two examiners performed the clinical exams to ensure 
coverage of the patients who came in as emergencies. Both 
examiners were trained to perform research techniques by the 
same clinical research coordinator. Both examiners assessed 
patients from both groups.
Evaluation of comorbidities and airflow limitation
Comorbidities were measured using the Charlson comorbidity 
index.13 Anxiety and depression were assessed using the 
Hospital Anxiety and Depression Scale (HADS, maximum 
score 42).14 The HADS is split into anxiety (21 points) 
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and depression (21 points) subscales, and the scores are 
categorized as follows: 0–7 points, normal; 8–10 points, 
mild; 11–14 points, moderate; and 15–21 points, severe. 
Illness severity was measured using the Acute Physiology 
and Chronic Health Evaluation (APACHE-II, maximum 
score 71).15 The burden of COPD symptoms was measured 
using the COPD assessment test (CAT).16 The CAT scores 
are characterized as follows: 0–10 points, mild; 11–20 points, 
moderate; 21–30 points, severe; and 31–40 points, very 
severe, clinical impact.
Airflow limitation was measured according to standard-
ized spirometry guidelines17 using the EasyOneTM World-
spirometer device (NDD Medical Technologies). Absolute 
FEV
1
, FVC, FEV
1
:FVC, and percentage predicted measure-
ments were obtained.
Cognitive status
The presence of delirium was assessed with the confusion 
assessment method (CAM),18 a bedside diagnostic tool that 
consists of nine operationalized criteria from the Diagnostic 
and Statistical Manual of Mental disorders (DSM-III-R). 
The Montreal cognitive assessment (MoCA)19 was used to 
assess the following cognitive domains: visuoconstructional 
skills, executive function, naming, delayed recall, attention, 
language, abstraction, and orientation. MoCA was scored 
out of a total of 30 points, and a cutoff of less than 26 was 
considered indicative of mild cognitive impairment.
statistical analyses
Continuous data were described using mean ± SD, and 
categorical data were described as number (%) participants. 
Normally distributed variables were compared using the 
independent t-test and non-normally distributed variables by 
Mann–Whitney U tests. Categorical variables were compared 
using Chi-squared tests. Analysis of covariance (ANCOVA) 
was used to control for age, sex, and pack year smoking 
history, during the comparison of normally distributed 
continuous variables. Group-specific associations between 
MoCA and clinical measures were tested using Pearson’s 
correlation and corrected for age and sex. Pack year smoking 
history was not corrected in the correlational analysis in order 
to investigate its effect. Where values were not normally 
distributed they were log-transformed before correlations 
were performed. Variables, which were significantly associ-
ated with MoCA, were further analyzed using ANCOVA. 
The ANCOVA model tested for the following main effects: 
dependent variable, MoCA total; fixed factors, group (COPD/
HF); covariates, age, sex, random glucose concentration, and 
pack year smoking history. The following interactions were 
also assessed – group by random glucose concentration and 
group by pack year smoking history. All statistical analyses 
were performed using IBM SPSS® (version 21.0).
Results
Patient demographics
A total of 20 COPD patients and 20 patients with HF were 
recruited. Demographics and clinical characteristics are 
compared in Table 1.
COPD and hF patients have similar 
comorbidities and acute illness severity
COPD patients and HF patients were well-matched for age, 
comorbidities (Charlson comorbidity index), and acute 
illness severity (APACHE-II score). As expected, COPD 
patients had worse airflow obstruction, greater smoking 
pack years, and more respiratory symptoms (CAT) and 
were more likely to be receiving bronchodilators (beta-2 
agonists and anticholinergics) and either inhaled or systemic 
corticosteroids. Conversely, HF patients were more likely to 
be taking cardiac medications such as diuretics, angiotensin-
converting enzyme (ACE) inhibitors, beta-blockers, and 
aldosterone antagonists. Interestingly, despite the differ-
ences in underlying diagnosis, both groups had elevated 
systemic inflammatory markers (C-reactive protein [CRP]). 
COPD patients had a higher circulating white blood count, 
????????????
?????????????????
????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????? ????
Figure 1 Flowchart of patient recruitment.
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which in the absence of differences in CRP is most likely 
due to systemic corticosteroid treatment. The groups were 
well-matched for other factors that might affect cognition, 
including alcohol consumption and sedative medication. 
COPD patients were significantly more anxious, but not more 
depressed, than patients with HF (Table 1). A total of 50% 
of people with HF and only 10% of people with COPD had 
diabetes mellitus (P=0.014). Random blood glucose did not 
differ between groups.
Cognitive impairment is common in 
COPD patients even when delirium is 
infrequent
A total of 15% of the patients in the COPD group showed 
evidence of delirium, compared to no patients in the HF 
group. The MoCA score was 4 points (95% CI 1–7) lower in 
COPD patients than in people with HF (mean ± SD, COPD 
20.6±5.6; HF 24.8±3.5, P=0.007). Statistical significance 
was lost after controlling for age, sex, and smoking pack 
year history (P=0.292). Using the MoCA score ,26 points 
as suggestive of cognitive impairment, 90% of people in the 
COPD group had cognitive impairment compared to 55% 
of people in the HF group. Reviewing MoCA sub-domains, 
COPD patients scored significantly lower in the cognitive 
domains of visuospatial function, executive function, and 
attention. Naming, language, abstraction, delayed recall, 
and orientation were not significantly different between the 
groups (Table 2).
In COPD patients, poor cognitive 
performance is associated with greater 
smoking history but not lung function or 
oxygen saturation
In the COPD group, MoCA score was inversely correlated 
with smoking pack year history (Table 3). There was no 
association between MoCA score and inflammatory markers 
(white blood cell count and CRP), hypoxemia (oxygen satu-
rations), lung function (FEV
1
% predicted), illness severity 
(APACHE-II, CAT), anxiety and depression (HADS), or 
random glucose concentration.
In hF patients, poor cognitive 
performance was associated with higher 
random blood glucose concentration
In people with HF, MoCA score was negatively correlated 
with random glucose concentration (Table 4). There was no 
Table 1 Clinical and demographic characteristics of participants
COPD (n=20) Heart failure (n=20) P-value
Age (years) 73±10 76±11 0.392
sex, n (%) (male) 8 (40%) 14 (70%) 0.057
Charlson index 1.3±1.9 1.6±1.5 0.314
APAChe-II score 15.4±3.5 15.9±3.0 0.565
smoking history (pack years) 51.5±35.0 11.1±15.6 0.001
Alcohol (units/week) 4.5±7.1 9.1±13.1 0.265
Admission to assessment (days) 3.1±3.4 7.9±11.1 0.149
FeV1 (% predicted) 42±19 53±16 0.101
FeV1:FVC (%) 56±14 71±16 0.024
Oxygen saturations (%) 93±4 97±2 0.001
hADs anxiety (maximum 21 points) 9±6 6±4 0.047
hADs depression (maximum 21 points) 10±4 9±4 0.216
C-reactive protein (mg/l) 36.3±49.7 31.3±31.0 0.512
White blood cell count (109/l) 13±6 9±3 0.003
random glucose (mmol/l) 8.2±2.8 8.0±3.0 0.683
Total number of drugs (n) 8.6±3.3 9.9±3.2 0.229
Drugs for COPD (n)a 3.7±0.9 0.6±1.1 ,0.001
Drugs for heart failure (n)b 0.6±0.6 2.8±0.6 ,0.001
Drugs affecting cognition (n)c 0.8±1.2 0.4±0.8 0.162
CAT (maximum 40 points) 27.8±6.4 21.4±8.4 0.010
Notes: Bold values denote statistical significance. aBeta-2 agonists, anticholinergics, and corticosteroids. bDiuretics, angiotensin-converting enzyme inhibitors, beta-blockers, 
and aldosterone antagonists. cOpioids, sedatives, antimuscarinics, and antidepressants.
Abbreviations: APAChe, Acute Physiology and Chronic health evaluation; CAT, COPD assessment test; hADs, hospital Anxiety and Depression scale.
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association between MoCA score and inflammatory markers 
(white blood cell count and CRP), hypoxemia (oxygen satu-
rations), lung function (FEV
1
% predicted), smoking pack 
years, illness severity (APACHE-II, CAT), or anxiety and 
depression (HADS).
In the whole group, age, random glucose 
concentration, and pack year smoking 
history were independently associated 
with cognitive function
The relationship between MoCA and underlying diagnosis 
(COPD or HF) was explored using an ANCOVA (Table 5). 
Group allocation, age, and sex were included in the model, 
along with factors that individually correlated with the MoCA 
in COPD and HF (smoking pack year history and random 
glucose concentration, respectively, Tables 3 and 4). In this 
model, diagnosis was not a significant determinant of cog-
nitive function. However, age (P=0.012), random glucose 
concentration (P=0.041), and pack year smoking history 
(P=0.050 – borderline statistical significance) were signifi-
cantly associated with cognitive function.
Discussion
The aim of this study was to determine if cognitive impair-
ment was more prevalent in people hospitalized with COPD 
exacerbations than in people hospitalized due to decompen-
sated HF. We found that patients with an acute exacerbation 
of COPD on average scored 4 points worse on the MoCA and 
were significantly more likely to have cognitive impairment, 
defined as MoCA ,26, than those with decompensated HF. 
Statistical differences in cognitive function between groups 
did not survive adjustment for age, sex, and pack year 
smoking history. ANCOVA in the whole group found that 
age, random glucose concentration, and pack year smoking 
history, but not underlying diagnosis (COPD or HF), were 
independent determinants of cognitive function.
Table 2 Cognitive assessment
MoCA cognitive domain COPD (n=20) Heart failure (n=20) P-value
Total (maximum 30 points) 20.6±5.6 24.8±3.5 0.007
Visuospatial function (maximum 2 points) 0 (1) 2 (1) 0.003
executive function (maximum 3 points) 2 (1) 3 (1) 0.035
naming (maximum 3 points) 3 (1) 3 (1) 0.947
Attention (maximum 6 points) 4 (3) 6 (2) 0.020
language (maximum 3 points) 2 (2) 3 (1) 0.068
Abstraction (maximum 2 points) 1 (2) 2 (1) 0.165
Delayed recall (maximum 5 points) 3 (4) 3 (2) 0.718
Orientation (maximum 6 points) 6 (0) 6 (0) 0.738
Notes: gaussian data are presented as mean ± SD and non-Gaussian data are presented as median (IQR). Bold values denote statistical significance where P,0.05.
Abbreviation: MoCA, Montreal cognitive assessment.
Table 3 Correlations with MoCA in COPD
R value P-value
APAChe-II score* 0.352 0.152
smoking history (pack years)* -0.536 0.022
FeV1 (% predicted) -0.098 0.740
Oxygen saturations (%) -0.319 0.197
random glucose (mmol/l)* -0.447 0.145
White blood cell count (109/l) -0.180 0.476
CrP (mg/l)* -0.447 0.081
CAT -0.277 0.266
hADs total -0.443 0.065
Notes: Bold values denote statistical significance. *Non-Gaussian variables were log 
transformed for parametric analysis. Data presented are corrected for age and sex.
Abbreviations: APAChe, Acute Physiology and Chronic health evaluation; 
CAT, COPD assessment test; CrP, C-reactive protein; hADs, hospital Anxiety 
and Depression scale; MoCA, Montreal cognitive assessment.
Table 4 Correlations with MoCA in heart failure
R value P-value
APAChe-II score* -0.105 0.679
smoking history (pack years)* -0.014 0.974
FeV1 (% predicted) -0.025 0.948
Oxygen saturations (%) -0.188 0.456
random glucose (mmol/l)* -0.676 0.011
White blood cell count (109/l) -0.348 0.158
CrP (mg/l)* -0.299 0.229
CAT -0.189 0.452
hADs total -0.394 0.105
Notes: Bold values denote statistical significance. *Non-Gaussian variables were log 
transformed for parametric analysis. Data presented are corrected for age and sex.
Abbreviations: APAChe, Acute Physiology and Chronic health evaluation; 
CAT, COPD assessment test; CrP, C-reactive protein; hADs, hospital Anxiety 
and Depression scale; MoCA, Montreal cognitive assessment.
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Our findings of significant cognitive impairment in COPD 
patients hospitalized with exacerbations are consistent with 
other studies. Dodd et al11 reported that people hospitalized 
for COPD have greater cognitive impairment than stable 
outpatients with COPD and age-matched controls. That study 
is not directly comparable to ours as hospitalized patients in 
the Dodd study were at the point of discharge. López-Torres 
et al20 reported a mean MoCA total score of 19.28±2.08 points 
in 48 patients hospitalized for acute exacerbation of COPD 
at admission, which is similar to the MoCA total of COPD 
patients in our study at 20.6±5.6 points. Furthermore, con-
sistent with our work, visuospatial function, executive func-
tion, and attentional deficits have previously been reported 
in COPD.6,21 Our study extends the findings of previous 
investigations in that we show that cognitive impairment in 
hospitalized COPD patients is greater than that in a hospital-
ized comparator group with decompensated HF.
We explored potential reasons underlying differences in 
cognition between hospitalized patients with COPD exac-
erbations or decompensated HF. Pack year smoking history 
differed markedly between the groups and was associated 
with cognitive dysfunction in COPD patients, independent of 
age and sex. In COPD, smoking load is significantly associ-
ated with more severe lung disease22,23 and increased risk of 
hospitalization.24 Smoking is also a well-recognized cause 
of vascular disease,25 which can impair cerebral perfusion, 
altering cognition.26 Moreover, cigarette smoke is thought to 
contain particulates which have a direct neurotoxic effect.27 
Greater smoking history could therefore contribute both to 
an increased risk of hospitalization and to the development 
of cognitive impairment, explaining the association. Smoking 
history of .10 pack years was an inclusion criterion for 
the COPD group and not for the HF group, who comprised 
people with HF from diverse etiology. The relatively light 
smoking load in those with HF could be considered less 
deleterious to cognitive function, which could explain why 
correcting for its effect removed the significant difference 
in MoCA total between the groups, despite patients with 
HF being older. ANCOVA showed that smoking pack year 
history marginally missed significance as a predictor of 
cognitive impairment, possibly due to a lack of statistical 
power and that this was not a group dependent effect. This 
suggests that cognitive impairment is not COPD specific but 
a smoking-specific effect.
Random glucose concentration was inversely correlated 
with MoCA in HF but not in COPD patients. In HF patients, 
elevated random glucose concentration could merely have 
been a marker for underlying diabetes, which affected 50% 
patients, and is independently associated with cognitive 
impairment.28 Mean random glucose concentration was the 
same in COPD patients as in HF patients, despite only 10% 
COPD patients having diagnosed diabetes mellitus. Elevated 
blood glucose is common during COPD exacerbations,29 at 
least in part due to corticosteroid therapy.30 Despite there being 
no significant difference in random glucose concentrations 
between groups, the ANCOVA revealed that random glu-
cose concentration predicted cognitive function and that this 
was not diagnosis dependent. This is consistent with a larger 
study by Crane et al who reported that hyperglycemia may be 
a risk factor for dementia.31 Previous studies have proposed 
that “overspill” of inflammation from the lungs of COPD 
patients into the systemic circulation32 may promote a neuro-
inflammatory response.33 This could be particularly marked 
during exacerbations and drive cognitive impairment. In the 
present study, lack of differences in systemic inflammation 
(CRP) between groups and lack of associations of inflamma-
tory markers (CRP, white cell count) with cognitive function 
indicated that cognitive impairment in this hospitalized COPD 
group was not explained by inflammation. White cell count 
did differ between groups, but in the absence of a difference 
in serum CRP, this is most likely explained by corticosteroid 
treatment for COPD exacerbation. Corticosteroids can have 
neuropsychiatric side effects. However, we have previously 
shown that the more marked cognitive impairment seen in hos-
pitalized COPD patients does not resolve with recovery and 
cessation of corticosteroids.11 Several studies have reported 
a relationship between hypoxia and cognitive dysfunction in 
COPD.7,34,35 However, these studies are limited by variation 
in the definition of hypoxemia between studies, correlations 
are often weak, and most evidence relates to non-hospitalized 
COPD patients.6 Although in our study, oxygen saturations 
Table 5 AnCOVA model of relationships with MoCA
Variables F (1, 14) P-value Partial Eta 
squared
group (COPD/hF) 0.235 0.636 0.016
Age 8.406 0.012 0.375
sex 1.648 0.220 0.105
random glucose concentration 
(mmol/l)*
5.079 0.041 0.266
smoking history (pack years)* 4.585 0.050 0.247
group by random glucose 
concentration interaction
1.671 0.217 0.107
group by smoking history 
(pack years) interaction
0.884 0.363 0.059
Notes: Bold values denote statistical significance. *Non-Gaussian variables were log 
transformed for parametric analysis.
Abbreviations: AnCOVA, analysis of covariance; hF, heart failure; MoCA, 
Montreal cognitive assessment.
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Cognitive impairment in hospitalized patients
were lower in COPD than HF patients, there was no associa-
tion between oxygen saturations and cognitive impairment.
limitations
Studies in hospital inpatients with acute illness are difficult 
to conduct because recruitment depends on unpredictable 
hospital admissions and patients can be too unwell to partici-
pate when ill enough to be eligible. In this context, we were 
able to recruit 20 patients in each group. The small size of 
this study means that our results need to be interpreted with 
caution as there is a risk of type 2 error due to insufficient 
power. We selected people with HF as “controls” with a 
chronic disease other than COPD prone to hospitalization for 
exacerbations. COPD and HF affect people at similar ages 
and are associated with a similar background prevalence of 
cognitive impairment.1 Despite this, there were other signifi-
cant differences between groups, particularly in smoking and 
diabetes. Matching for these characteristics would have been 
desirable, although difficult.
Premorbid cognition was not measured in this study, 
which is known to be a major determinant of cognitive 
function in terms of brain reserve,36 so it is unclear how this 
might have influenced our analysis.
Cognitive impairment was measured using the MoCA. 
As a brief screening instrument, the MoCA has clinical utility 
as a general measure of cognitive impairment. Although we 
have analyzed the subdomains of the MoCA, which indicate 
that COPD patients have impairments in visuospatial func-
tion, executive function, and attention, an in-depth battery 
of neuropsychological tests would be required to assess 
this fully.
Associations between the MoCA and clinical characteris-
tics gave some clues as to the mechanisms underlying cogni-
tive impairment in hospitalized COPD patients. However, 
as this is a cross-sectional study it is not possible to attribute 
direction of causation.
Finally, as two examiners performed the clinical exams, 
inter-rater variability should have been calculated to deter-
mine the consistency and reliability of the scoring. Despite 
this, both examiners assessed patients from both patient 
groups so there was no opportunity for systematic bias 
to occur.
Cognitive impairment has a significant clinical impact 
for COPD patients. As patients hospitalized with COPD 
exacerbations appear particularly vulnerable to cognitive 
impairment, they may be the group who would benefit most 
from targeted interventions. Our study found that COPD 
patients performed significantly worse on the visuospatial, 
executive function and attention domains of the MoCA, 
compared to HF patients. Lezak et al37 described executive 
function as the ability to formulate goals, plan achievement, 
and perform behaviors effectively. Impairment in this area 
can result in inability to utilize and adhere to medication 
adequately as well as inability to perform other aspects of 
personal management. Visuospatial function involves the 
perception of orientation, spatial location, direction, and 
distance. Impairments in this area can lead to the inability 
to plan a route or leaving home and getting lost. Attention 
requires appropriate allocation of processing resources; 
therefore, dysfunction in this area would result in difficulty 
concentrating on tasks.38 Raising awareness of the existence 
of cognitive impairment, using a reliable tool, facilitated with 
support groups and health care contacts, may be the route to 
explore to ensure improved adherence to therapy and perhaps 
to reduce hospitalizations.
Conclusion
COPD patients hospitalized for exacerbations have marked 
cognitive impairment, which is not explained by hospi-
talization. Cognitive impairment is associated with pack 
year smoking history, rather than systemic inflammation 
or hypoxia, indicating that smoking could be an important 
underlying mechanism. In hospitalized patients with either 
COPD or HF, random blood glucose was associated with 
cognitive impairment, indicating a potential contributing 
role for diabetes. Awareness of the prevalence of cognitive 
impairment in hospitalized patients with COPD has impor-
tance for treatment adherence and discharge planning to 
reduce readmissions.
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